{"DataElement":{"publicId":"7414254","version":"1","preferredName":"Recombinant Erwinia asparaginase JZP-458 Not Administered Reason","preferredDefinition":"Indicator for reason RC-P was not administered.","longName":"RCP_NOT_ADMN_IND","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7414253","version":"1","preferredName":"Recombinant Erwinia asparaginase JZP-458 Negation Administered","preferredDefinition":"A recombinant form of asparaginase (Erwinia asparaginase; crisantaspase) derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration of recombinant Erwinia asparaginase JZP-458, the recombinant asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. JZP-458 can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products._An operation in which a term denies or inverts the meaning of another term or construction._The act of having given something (e.g., a medication or test).","longName":"7391897v1.0:2207837v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7391897","version":"1","preferredName":"Recombinant Erwinia asparaginase JZP-458","preferredDefinition":"A recombinant form of asparaginase (Erwinia asparaginase; crisantaspase) derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration of recombinant Erwinia asparaginase JZP-458, the recombinant asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. JZP-458 can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.","longName":"C167120","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Erwinia asparaginase JZP-458","conceptCode":"C167120","definition":"A recombinant form of asparaginase (Erwinia asparaginase; crisantaspase) derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration of recombinant Erwinia asparaginase JZP-458, the recombinant asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. JZP-458 can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC9D11A-2D3D-1FA5-E053-4EBD850A6C61","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207837","version":"1","preferredName":"Not Administered","preferredDefinition":"Not; used for negation of a word or group of words.:Given.","longName":"C25594:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3219-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEE54BA9-925E-4176-E053-4EBD850A91B8","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"SETRAKIN","dateModified":"2020-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7414246","version":"1","preferredName":"Not Administered Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"7414246v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEE51443-DF7F-40EF-E053-4EBD850AD8C2","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"ONEDATA","dateModified":"2020-09-09","deletedIndicator":"No"},{"value":"Stroke","valueDescription":"Stroke","ValueMeaning":{"publicId":"6063461","version":"1","preferredName":"Stroke","longName":"6063461","preferredDefinition":"A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stroke, CTCAE","conceptCode":"C143862","definition":"A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"64948057-0829-1045-E053-F662850AD8CF","latestVersionIndicator":"Yes","beginDate":"2018-02-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-02-06","modifiedBy":"MAESKEB","dateModified":"2018-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEE51443-DF89-40EF-E053-4EBD850AD8C2","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"ONEDATA","dateModified":"2020-09-09","deletedIndicator":"No"},{"value":"Drug shortage","valueDescription":"Drug shortage","ValueMeaning":{"publicId":"7391865","version":"1","preferredName":"Drug shortage","longName":"7391865","preferredDefinition":"Drug shortage","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC97179-89DB-2BC4-E053-4EBD850AE7E5","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEE51443-DF93-40EF-E053-4EBD850AD8C2","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"ONEDATA","dateModified":"2020-09-09","deletedIndicator":"No"},{"value":"Pancreatitis","valueDescription":"Pancreatitis","ValueMeaning":{"publicId":"2559694","version":"1","preferredName":"Pancreatitis","longName":"2559694","preferredDefinition":"Inflammation of the pancreas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatitis","conceptCode":"C3306","definition":"Inflammation of the pancreas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B63B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEE51443-DF9D-40EF-E053-4EBD850AD8C2","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"ONEDATA","dateModified":"2020-09-09","deletedIndicator":"No"},{"value":"Not available at treatment site","valueDescription":"Not available at treatment site","ValueMeaning":{"publicId":"7551719","version":"1","preferredName":"Not available at treatment site","longName":"7551719","preferredDefinition":"Not available","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9573682-72C8-3D70-E053-4EBD850AF90B","latestVersionIndicator":"Yes","beginDate":"2021-01-20","endDate":null,"createdBy":"WOODC","dateCreated":"2021-01-20","modifiedBy":"ONEDATA","dateModified":"2021-01-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9573682-72E1-3D70-E053-4EBD850AF90B","beginDate":"2021-01-20","endDate":null,"createdBy":"WOODC","dateCreated":"2021-01-20","modifiedBy":"ONEDATA","dateModified":"2021-01-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2240632","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F9FA7953-8391-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-30","endDate":null,"createdBy":"PWEST","dateCreated":"2005-06-30","modifiedBy":"ONEDATA","dateModified":"2005-06-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEE51443-DF68-40EF-E053-4EBD850AD8C2","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"WOODC","dateModified":"2021-01-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Reason RC-P not received:","type":"Preferred Question Text","description":"Reason RC-P not received:","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"If Pegaspargase was discontinued, did the patient receive RC-P during this reporting period?","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Reason Rylaze not received:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEE45F5D-6E26-41C3-E053-4EBD850A1E37","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"WOODC","dateModified":"2021-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}